Rosiglitazone and Trametinib to treat basal bladder tumors [RNA-Seq]
To investigate the anti-tumor effect of Rosiglitazone+Trametinib in basal bladder cancer, we tested the drug combination in BBN-induced basal tumor mouse model in vivo and BBN-derived tumor cell line BBN963 in vitro. Overall design: Comparative gene expression profiling analysis of RNA-seq data for Rosiglitazone and Trametinib and vehicle treated basal tumor cells in vivo and in vitro. Comparative gene expression profiling analysis of RNA-seq data for all-trans retinoic acid and vehicle treated basal tumor BBN963 cells in vitro.